<DOC>
	<DOCNO>NCT02240355</DOCNO>
	<brief_summary>This multicenter , randomize , double-blind , 12-week , placebo-controlled multiple dose study investigate safety tolerability RO6885247 adult pediatric patient spinal muscular atrophy ( SMA ) .</brief_summary>
	<brief_title>A Study RO6885247 Adult Pediatric Patients With Spinal Muscular Atrophy ( MOONFISH )</brief_title>
	<detailed_description />
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Muscular Atrophy , Spinal</mesh_term>
	<mesh_term>Muscular Atrophy</mesh_term>
	<criteria>Males female , age 2 55 year inclusive 7 month inclusive Confirmed diagnosis 5qautosomal recessive SMA ( Types 1 3 ) , patient age 7 month clinical symptom attributable type 1 SMA 2 SMN2 copy Able willing provide inform consent comply study protocol . Alternatively , legally authorize representative must able consent patient assent must give subject wherever possible . Female patient childbearing potential male patient female partner childbearing potential must agree require contraceptive method define per protocol . For patient age 7 month , Gestational age 37 42 week consider small gestational age birth Concomitant previous participation investigational drug device study within 90 day prior screen Concomitant previous participation SMN2targeting antisense oligonucleotide study within 12 month prior screen Concomitant previous participation time gene therapy study For patient age 255 year , hospitalization pulmonary event within last 2 month plan time screen Surgery scoliosis last 6 month screen plan within 6 month screen Unstable gastrointestinal , renal , hepatic , endocrine cardiovascular system disease Clinically relevant ECG abnormality screen baseline ; personal family history ( first degree relative ) congenital long QT syndrome Clinically significant abnormality laboratory test result screen Any concomitant disease condition could interfere conduct study , pose unacceptable risk subject study Use prohibit medication per protocol within 90 day prior randomization . Patients inhaled corticosteroid , administer either nebulizer inhaler , allow . Recently initiate treatment ( within &lt; 6 month prior randomization ) oral salbutamol another beta2adrenergic agonist take orally allow . Patients oral salbutamol ( another beta2adrenergic agonist ) least 6 month randomization allow . Use inhale beta2adrenergic agonist allow . For patient age 7 month , patient require invasive ventilation tracheostomy , presence nonSMA related morbidity</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>